Clinical review: intensive care unit acquired weakness.

Hermans G, Van den Berghe G. · 2015

Read Clinical review: intensive care unit acquired weakness. by Hermans G, Van den Berghe G. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4526175.txt.

Introduction

Greet Hermans and Greet Van den Berghe review muscle weakness picked up in intensive care, in Critical Care in 2015. Many patients admitted with grave illness, major surgery, trauma, or burns grow weak during the stay itself, from nerve damage, muscle disease, or both. The weakness tends to be even on both sides, hits the limbs near the trunk and the breathing muscles hardest, and often spares the face.

Risk runs higher with severe illness at admission, sepsis, failure of several organs, long immobility, and high blood sugar; age adds risk too. Inside the body, faults in blood flow, electrical signaling, and energy use combine to waste muscle. Diagnosis relies on bedside strength testing in awake patients, scored on a standard sum scale.

Catalog record

CREATORHermans G, Van den Berghe G.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE59 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4526175

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Clinical review: intensive care unit acquired weakness By Greet Hermans, Greet Van den Berghe Published in: Critical Care DOI: 10.1186/s13054-015-0993-7 ABSTRACT Abstract A substantial number of patients admitted to the ICU because of an acute illness, complicated surgery, severe trauma, or burn injury will develop a de novo form of muscle weakness during the ICU stay that is referred to as “intensive care unit acquired weakness” (ICUAW). This ICUAW evoked by critical illness can be due to axonal neuropathy, primary myopathy, or both. Underlying pathophysiological mechanisms comprise microvascular, electrical, metabolic, and bioenergetic alterations, interacting in a complex way and culminating in loss of muscle strength and/or muscle atrophy. ICUAW is typically symmetrical and affects predominantly proximal limb muscles and respiratory muscles, whereas facial and ocular muscles are often spared. The main risk factors for ICUAW include high severity of illness upon admission, sepsis, multiple organ failure, prolonged immobilization, and hyperglycemia, and also older patients have a higher risk. The role of corticosteroids and neuromuscular blocking agents remains unclear. ICUAW is diagnosed in awake and cooperative patients by bedside manual testing of muscle strength and the severity is scored by the Medical Research Council sum score. In cases of atypical clinical presentation or evolution, additional electrophysiological testing may be required for differential diagnosis. The cornerstones of prevention are aggressive treatment of sepsis, early mobilization, preventing hyperglycemia with insulin, and avoiding the use parenteral nutrition during the first week of critical illness. Weak patients clearly have worse acute outcomes and consume more healthcare resources. Recovery usually occurs within weeks or months, although it may be incomplete with weakness persisting up to 2 years after ICU discharge. Prognosis appears compromised when the cause of ICUAW involves critical illness polyneuropathy, whereas isolated critical illness myopathy may have a better prognosis. In addition, ICUAW has shown to contribute to the risk of 1-year mortality. Future research should focus on new preventive and/or therapeutic strategies for this detrimental complication of critical illness and on clarifying how ICUAW contributes to poor longer-term prognosis. INTRODUCTION Generalized muscle weakness, which develops during the course of an ICU admission and for which no other cause can be identified besides the acute illness or its treatment, is labeled “intensive care unit acquired weakness” (ICUAW). ICUAW may affect peripheral as well as respiratory muscles. The “loss of flesh and strength” in patients with life-threatening infections was described in the nineteenth century [1]. However, it took another century before it was understood that ICUAW can be evoked either by critical illness polyneuropathy (CIP) [2], by critical illness myopathy (CIM) [3], or by both [4] during the course of critical illness. ICUAW is a frequent complication of critical illness and is associated with a high morbidity and mortality of acute critical illnesses. In addition, recent data revealed that ICUAW may also have longer-term consequences, beyond the hospitalization phase. For example, ICUAW may be an important contributor to the post intensive care syndrome (PICS) [5]. This term includes the physical, mental, and cognitive dysfunctions that are part of the persisting disabilities, which extend beyond the acute hospitalization and have major impact on the quality of life of the growing population of ICU survivors. This review aims to update the available knowledge regarding ICUAW, its clinical characteristics and diagnostic properties, the underlying mechanisms and predisposing factors, as well as its medical and socioeconomic consequences. In addition, possible avenues towards prevention and treatment of ICUAW will be reviewed. INCIDENCE ICUAW is a frequent problem. The reported incidence varies depending on the patient population studied and on the timing of the evaluation. Weakness at awakening was found to be present in 26–65 % of patients who were mechanically ventilated for 5–7 days, respectively [6, 7], and 25 % of these remained weak for at least another 7 days after awakening [8]. Among long-term ventilated patients (≥10 days) ICUAW was diagnosed in up to 67 % [9]. In another study 11 % of patients treated in the ICU for at least 24 hours developed ICUAW [10], and when the ICU stay increased to 7–10 days ICUAW at awakening was present in 24–55 % of patients [10–12]. In patients suffering from acute respiratory distress syndrome (ARDS), an ICUAW incidence of 60 % has been reported at the time of awakening [13], and at hospital discharge this incidence was still 36 % [14]. PATHOPHYSIOLOGY The mechanisms underlying ICUAW are complex and involve functional and structural alterations in both the muscles and the nerves. In CIP, the pathological finding is axonal degeneration [15]. The pathogenesis of such axonal degeneration remains incompletely understood, in part explained by the invasiveness of nerve biopsies. Factors that play a role are microvascular changes in the endoneurium evoked by sepsis [16], which promotes vascular permeability and allows penetration of toxic factors into the nerve ends [17]. The endoneural edema resulting from increased permeability may impair energy delivery to the axon followed by axonal death. Direct toxic effects and mitochondrial dysfunction evoked by hyperglycemia may contribute to this process [18–20]. Animal experiments also identified channelopathy as a cause of rapidly occurring but reversible neuropathy [21]. Whether such a channelopathy also occurs in ICU patients, as a functional precursor of axonal degeneration that is found later in the course of critical illness, remains unclear [22]. In CIM, several factors are thought to play a role by negatively affecting muscle structure and function, all interacting in a complex manner [22]. A detailed overview of mediators and molecular mechanisms involved was published recently [23]. First, muscle atrophy can occur quite early during critical illness [24]. Muscle atrophy is brought about by increased breakdown and decreased synthesis of muscle protein [24, 25]. Several processes during critical illness may promote such wasting of muscle protein, which preferentially involves myosin [25, 26]. These include inflammation, immobilization, the endocrine stress responses, the rapidly developing nutritional deficit, impaired microcirculation, and denervation [22, 27, 28]. Key proinflammatory mediators involved include tumor necrosis factor alpha, interleukin-1, and interleukin-6 [23]. Recently, another stress-induced cytokine, growth and differentiation factor-15 (GDF-15), a member of the transforming growth factor beta super family, was identified as a mediator of muscle atrophy during critical illness [29]. In addition to muscle atrophy, other factors may contribute to decreased muscle function. Muscle membrane inexcitability induced by sodium channel dysfunction is an early finding in CIM [30] and predicts the development of clinical muscle weakness [31]. An altered intracellular calcium homeostasis, affecting the excitation–contraction coupling, has also been shown to contribute to reduced contractility in animal sepsis models [32, 33]. The muscles of septic patients show signs of bioenergetic failure, comprising oxidative stress, mitochondrial dysfunction, and ATP depletion [34]. Finally, muscle atrophy and weakness are not synonymous [22]. Indeed, muscle quality might be even more important than muscle mass in determining muscle function and the development of ICUAW [35]. Autophagy, which is a cellular housekeeping system that mediates removal of damaged large organelles and protein aggregates, is an important factor in maintaining muscle fiber integrity [36], and deficient autophagy may have a crucial role in the development of ICUAW [35]. RISK FACTORS Several risk factors for the development of neuromuscular complications in the ICU have been reported. At the time when CIP was first described, sepsis, systemic

Read the complete text